Figure 2From: Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: A parallel, randomized, double blind studyPharmacodynamic variables. Data correspond to patients who received 100 IU/Kg of Heberitro (solid line) or Eprex (dashed line). (A): average reticulocyte counts increments; (B): percentage mean reduction in serum iron. Standard deviations are not shown for the sake of simplicity of the illustration.Back to article page